RMSL RemSleep Holdings

RemSleep Holdings Inc. Commences Trading on OTCQB

RemSleep Holdings Inc. Commences Trading on OTCQB

Tampa, FL, July 27, 2022 (GLOBE NEWSWIRE) -- RemSleep Holdings Inc. (OTCQB: RMSL), a medical device manufacturer dedicated to forever improving the level of treatment provided to obstructive Sleep Apnea patients, is pleased to announce that the company’s common shares will begin trading on the OTCQB Market as of the opening of the market on today, July 27, 2022.

The OTCQB is the premiere marketplace for entrepreneurial and development stage U.S. and international companies that are committed to providing a high-quality trading and information experience for their investors. To qualify for OTCQB, companies must meet high financial standards, follow best practice corporate governance, and demonstrate compliance with applicable securities laws.

Investors can find financial disclosure and Real-Time Level 2 quotes for the Company at . The company’s tier upgrade has been noted on the RemSleep profile on OTC Markets.

“Now that we have achieved this milestone, we look forward to broadening our shareholder base, as well as maintaining the utmost transparency with our investors,” said Tom Wood, RemSleep CEO.

About RemSleep Holdings Inc.

RemSleep Holdings Inc. is a medical device manufacturer dedicated to forever changing the level of treatment provided to obstructive Sleep Apnea patients. Our focus is primarily designing and manufacturing devices and products for the treatment of Sleep Apnea and other respiratory conditions. With over 30 years of collective experience in CPAP therapy, the RemSleep team has extensive knowledge and understanding of CPAP and the challenges of patient compliance. We diligently strive for our products to make the difference and improve the condition of those suffering from Sleep Apnea. 

Forward-Looking Statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words "may", "will", "should", "continue", "expect", "anticipate", "estimate", "believe", "intend", "plan" or "project" or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company's ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company to obtain sufficient financing to execute the Company's business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company's public disclosure record on file with the relevant securities regulatory authorities. No information in this press release should be construed as any indication whatsoever of the Company's future revenues, results of operations or stock price. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Investor Relations Contact:

Preya Narain

347-837-0626



EN
27/07/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on RemSleep Holdings

 PRESS RELEASE

REMSleep Patent Application Has Been Allowed by the United States Pate...

REMSleep Patent Application Has Been Allowed by the United States Patent and Trademark Office CLEARWATER, FL, Sept. 03, 2024 (GLOBE NEWSWIRE) -- REMSleep Holdings, Inc. (OTCQB: RMSL) announces that another utility patent for its Nasal Ventilation System has been allowed by the United States Patent and Trademark Office.  REMSleep will file the necessary paperwork to pay for issuance and, thereafter, REMSleep should be awarded a patent in approximately 8 weeks.  REMSleep will maintain a continuation application for adding any improvements and/or changes to the patent lineage. REMSleep is...

 PRESS RELEASE

REMSleep Holdings Inc. Issues Shareholder Letter

REMSleep Holdings Inc. Issues Shareholder Letter Company Unveils Internal Corporate Goal of Capturing 10% of the CPAP Mask Market Within 24 Months CLEARWATER, Fla., Aug. 06, 2024 (GLOBE NEWSWIRE) -- REMSleep Holdings, Inc. (OTCQB: RMSL), a leader in innovative sleep apnea products, published the following letter to shareholders. Dear REMSleep Shareholders and Interested Investors: Our company’s primary focus is two-fold. First, we are dedicated to providing high-quality products and experiences for CPAP therapy to support our customers and their families. Second, we are intensely ...

 PRESS RELEASE

REMSleep Holdings, Inc. Announces Distributor Request for DELTAWAVE Na...

REMSleep Holdings, Inc. Announces Distributor Request for DELTAWAVE Nasal Pillows System Samples CLEARWATER, Fla., July 24, 2024 (GLOBE NEWSWIRE) -- REMSleep Holdings, Inc. (OTCQB: RMSL), a leader in innovative sleep apnea products, is thrilled to announce that a significant distributor in the CPAP industry has requested samples of its new nasal interface, the DELTAWAVE Nasal Pillows System. This request marks a pivotal step in REMSleep's mission to revolutionize sleep apnea treatment with cutting-edge technology and superior comfort. REMSleep is currently in the process of preparing the...

 PRESS RELEASE

REMSleep Holdings Inc. Announces Strategic Marketing Plan for DELTAWAV...

REMSleep Holdings Inc. Announces Strategic Marketing Plan for DELTAWAVE Nasal Pillows System CLEARWATER, Fla., July 17, 2024 (GLOBE NEWSWIRE) -- REMSleep Holdings Inc. (OTCQB: RMSL), a pioneer in sleep apnea treatment solutions, is thrilled to announce a comprehensive marketing strategy for its revolutionary DELTAWAVE Nasal Pillows System. This strategic plan aims to significantly expand the market presence of DELTAWAVE by identifying and partnering with key distributors nationwide The DELTAWAVE Nasal Pillows System, designed with cutting-edge technology, offers an innovative solution fo...

 PRESS RELEASE

REMSleep Holdings Inc. Receives 510(K) Clearance on Product

REMSleep Holdings Inc. Receives 510(K) Clearance on Product CLEARWATER, Fla., July 09, 2024 (GLOBE NEWSWIRE) -- REMSleep Holdings, Inc. (OTCQB: RMSL) announces the company has been awarded 510(K) Clearance for the new Deltawave CPAP Pillows Interface mask. The company would like to share the following correspondence with its shareholders: Re: K233415Trade/Device Name: DELTAWAVE Nasal Pillows SystemRegulation Number: 21 CFR 868.5905Regulation Name: Noncontinuous Ventilator (IPPB)Regulatory Class: Class IIProduct Code: BZDDated: October 4, 2023Received: October 10, 2023 Dear Judy Strzepek...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch